SecBot SecBot
PRESS-RELEASE ·Filed May 11, 2026

APGE

Apogee Therapeutics
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The EPS beat and strong cash runway are positive, but the stock's move will hinge on APEX Phase 2 Part B data expected in Q2 2026. Monitor for the Part B readout and any updates on asthma/EoE trial designs later this year. The $403M offering was already priced in post-March 2026 readout; near-term focus is on execution toward Phase 3.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$84.60
T+0 close · May 11, 2026 · via day close
Latest settled
+58.66%
T+60 · $134.23
Vs SPY
+54.27%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $84.60entry
  2. T+1 · 6mo ago −1.97%α −1.84% · $82.93
  3. T+5 · 6mo ago −6.91%α −6.83% · $78.75
  4. T+20 · 5mo ago +0.47%α +0.78% · $85.00
  5. T+60 · 3mo ago +58.66%α +54.27% · $134.23

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Apogee Therapeutics reported Q1 2026 EPS of -$1.03, a 9% beat vs consensus of -$1.13, with no revenue. The company highlighted durable 52-week Phase 2 data for zumilokibart in atopic dermatitis and a $403M upsized equity offering extending cash runway into 2029. Net loss widened to $74.1M from $55.3M YoY on higher R&D and G&A spend, but the pipeline catalyst (Phase 2 Part B data in Q2 2026 and Phase 3 initiation in 2H 2026) overshadows the loss expansion.

Key Financial Metrics

EPS
−$1.03
est −$1.13 · +8.8%
Rating
beat

Key Facts

  • EPS of -$1.03 beat consensus of -$1.13 by 9%
  • No revenue (pre-commercial biotech)
  • Cash position $1.3B as of March 31, 2026, up from $902.9M at Dec 31, 2025, following $403M upsized equity offering
  • Net loss widened to $74.1M from $55.3M YoY on higher R&D ($60.8M vs $46.4M) and G&A ($22.0M vs $16.7M) expenses
  • APEX Phase 2 Part A 52-week data showed durable maintenance with 3- and 6-month dosing; 75-85% of Week 16 EASI-75 responders maintained at Week 52
  • APEX Phase 2 Part B 16-week data expected in Q2 2026; Phase 3 initiation in AD expected in 2H 2026
  • Positive Phase 1b asthma data reported January 2026; expansion into asthma and EoE trials planned later this year
  • Cash runway into 2029 supports BLA filing for zumilokibart in AD

Financial Impact

EPS beat of 9% on consensus -$1.13; cash position strengthened to $1.3B from $902.9M

epscashnet_loss

Risk Factors

  • Clinical trial failure risk, Part B data may not replicate Part A durability
  • Dilution from $403M equity offering already completed; no further near-term dilution expected
  • Widening net loss trajectory with no near-term revenue; reliance on capital markets for future funding
  • Competitive landscape in AD (DUPIXENT, lebrikizumab, others)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3291754

Track record

31 reports on APGE

Performance horizon

8 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +73.31% at T+60 after the May 27, 2026 report. 11 of 12 went positive at some point.

Filters
  1. Sep 14, 20269w ago 15-12G Neutral 4/10 No price data
  2. Sep 3, 202610w ago 25-NSE Bullish 8/10 Entry $135.06 No price data
  3. Sep 3, 202610w ago 8-K Bullish 8/10 Entry $135.06 No price data
  4. Aug 11, 202613w ago 8-K Bullish 7/10 Entry $134.55 No price data
  5. Aug 10, 202614w ago 8-K Bullish 8/10 No price data
  6. Aug 10, 202614w ago Press Release Bullish 8/10 Entry $134.65 No price data
  7. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $134.49 to $135.07 ▲ +0.43% −0.17% vs SPY
  8. Aug 3, 202615w ago DEFA14A Bullish 5/10 Entry $134.19 to $135.08 ▲ +0.66% +1.90% vs SPY
  9. Jul 10, 202618w ago Insider Cluster Neutral 2/10 Entry $133.82 to $134.65 ▲ +0.62% −2.56% vs SPY
  10. Jun 26, 202620w ago DEFA14A Bullish 6/10 Entry $132.61 to $134.28 ▲ +1.26% +1.54% vs SPY
Showing 10 of 31

US Market Status

Market Closed · Opens Wed (11h 17m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026